Northern Trust Corp Grows Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Northern Trust Corp raised its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 32.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 674,640 shares of the medical equipment provider's stock after acquiring an additional 166,248 shares during the quarter. Northern Trust Corp owned about 0.15% of Smith & Nephew SNATS worth $19,140,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hara Capital LLC increased its stake in shares of Smith & Nephew SNATS by 391.4% in the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 1,957 shares in the last quarter. Barclays PLC acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter valued at about $431,000. First Trust Advisors LP acquired a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth about $248,000. Stifel Financial Corp increased its holdings in Smith & Nephew SNATS by 19.5% during the 4th quarter. Stifel Financial Corp now owns 48,292 shares of the medical equipment provider's stock worth $1,187,000 after purchasing an additional 7,893 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Smith & Nephew SNATS in the fourth quarter worth approximately $2,831,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SNN has been the topic of several analyst reports. Canaccord Genuity Group lifted their target price on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research report on Monday, August 18th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a report on Saturday. Six research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $36.00.

Smith & Nephew SNATS Trading Up 1.2%

Shares of Smith & Nephew SNATS stock traded up $0.46 on Wednesday, reaching $37.36. The company had a trading volume of 538,338 shares, compared to its average volume of 837,086. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $37.65. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The firm's 50-day moving average price is $33.27 and its two-hundred day moving average price is $29.88. The firm has a market cap of $16.36 billion, a price-to-earnings ratio of 17.30, a P/E/G ratio of 1.03 and a beta of 0.71.

Smith & Nephew SNATS Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be paid a $0.285 dividend. This represents a dividend yield of 210.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS's dividend payout ratio (DPR) is presently 41.20%.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.